Eli Lilly and Company expands its oncology portfolio through the Lilly Ajax Therapeutics acquisition, targeting breakthroughs in myeloproliferative neoplasms with AJ1-11095.
The Foundayo launch impact on Eli Lilly has been swift and sharp — while FDA approval of orforglipron marked a historic first for oral GLP-1 obesity treatment, early prescription data trailing Novo Nordisk’s Wegovy sent LLY stock down as much as 4.3%, forcing analysts to slash 2026 revenue forecasts from $5 billion to just $1.3–1.6 billion.
Indian health officials have intercepted a shipment of suspected counterfeit weight-loss medication. The discovery of fake Mounjaro pens underscores a growing global trend of illicit medical supplies entering the market through online platforms like Alibaba.
Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.
Topline results from the Phase 3 BRUIN CLL-322 trial confirm that Jaypirca significantly extended progression-free survival when added to a venetoclax regimen.
Eli Lilly has officially received Foundayo FDA approval for orforglipron, the first daily non-peptide oral GLP-1 receptor agonist that offers significant weight loss results without the dietary restrictions of previous oral treatments.
Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion, signaling a major expansion into the sleep medicine market through innovative orexin receptor agonists.
EBGLYSS durable efficacy has taken center stage in the dermatology world as Eli Lilly and Company (NYSE: LLY) recently announced groundbreaking four-year data from its [Read More…]
Eli Lilly and Company announced positive topline results from TRANSCEND-T2D-1, a landmark Phase 3 clinical trial evaluating retatrutide, an investigational triple hormone receptor agonist. The trial results demonstrate [Read More…]
EBGLYSS (lebrikizumab) achieves groundbreaking Phase 3 results in children 6 months-18 years with moderate-to-severe atopic dermatitis. 63% achieved EASI-75 skin improvement. Learn about this selective IL-13 inhibitor breakthrough.
